TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Brief Summary: The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery.

The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.


Options:
A: Arm Label: Restrictive arm (intervention); Type: EXPERIMENTAL; Interventions: Procedure: Less red blood cell transfusions | Arm Label: Standard care arm (comparator); Type: ACTIVE_COMPARATOR; Interventions: Procedure: More red blood cell transfusion (standard transfusion strategy in PICU) | Intervention Type: PROCEDURE; Name: Less red blood cell transfusions; Assigned to Arm(s): Restrictive arm (intervention) | Intervention Type: PROCEDURE; Name: More red blood cell transfusion (standard transfusion strategy in PICU); Assigned to Arm(s): Standard care arm (comparator)
B: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers
C: Arm Label: Blood transfusion triggers of 24% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 24% | Arm Label: Blood transfusion triggers of 28% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 28% | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 24%; Assigned to Arm(s): Blood transfusion triggers of 24% hematocrit value | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 28%; Assigned to Arm(s): Blood transfusion triggers of 28% hematocrit value
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Brief Summary: The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery.

The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.


Options:
A: Arm Label: Blood transfusion triggers of 24% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 24% | Arm Label: Blood transfusion triggers of 28% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 28% | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 24%; Assigned to Arm(s): Blood transfusion triggers of 24% hematocrit value | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 28%; Assigned to Arm(s): Blood transfusion triggers of 28% hematocrit value
B: Intervention Type: DRUG; Name: Red blood cell transfusion; Assigned to Arm(s): N/A
C: Arm Label: Liberal RBC Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Other: Liberal Red Blood Cell Transfusion Strategy | Arm Label: Restrictive RBC Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Red Blood Cell Transfusion Strategy | Intervention Type: OTHER; Name: Liberal Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Liberal RBC Transfusion Strategy | Intervention Type: OTHER; Name: Restrictive Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Restrictive RBC Transfusion Strategy
D: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Brief Summary: The primary purpose of this study is to determine the best blood level to begin transfusing red blood cells in individuals undergoing cardiac surgery.

The secondary aim is to determine the impact of red cell transfusion on health-related quality of life following surgery.


Options:
A: Arm Label: Blood transfusion triggers of 24% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 24% | Arm Label: Blood transfusion triggers of 28% hematocrit value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood transfusion at hematocrit value less than 28% | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 24%; Assigned to Arm(s): Blood transfusion triggers of 24% hematocrit value | Intervention Type: PROCEDURE; Name: Blood transfusion at hematocrit value less than 28%; Assigned to Arm(s): Blood transfusion triggers of 28% hematocrit value
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Packed Red Blood Cell Transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Packed Red Blood Cell Transfusion | Intervention Type: PROCEDURE; Name: Packed Red Blood Cell Transfusion; Assigned to Arm(s): 1, 2
C: Arm Label: Single-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Arm Label: Multiple-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Intervention Type: BIOLOGICAL; Name: Blood Transfusion; Assigned to Arm(s): Multiple-Unit Blood Transfusion Protocol, Single-Unit Blood Transfusion Protocol
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red Blood Cell Transfusion | Intervention Type: BIOLOGICAL; Name: Red Blood Cell Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5
Brief Summary: The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: formoterol | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: formoterol; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
C: Arm Label: beclometasone /formoterol; Type: EXPERIMENTAL; Interventions: Drug: beclomethasone/formoterol (100/6µg) pMDI | Arm Label: Beclomethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclometasone dipropionate 250 µg/unit dose pMDI | Arm Label: Formoterol powder 12 µg/unit dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol powder 12 µg/unit dose | Intervention Type: DRUG; Name: beclomethasone/formoterol (100/6µg) pMDI; Assigned to Arm(s): beclometasone /formoterol | Intervention Type: DRUG; Name: Beclometasone dipropionate 250 µg/unit dose pMDI; Assigned to Arm(s): Beclomethasone | Intervention Type: DRUG; Name: Formoterol powder 12 µg/unit dose; Assigned to Arm(s): Formoterol powder 12 µg/unit dose
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/formoterol fumarate 100/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/formoterol fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Test Treat Strategy to Prevent Ulcerative Colitis Relapse
Brief Summary: The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels \<50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.


Options:
A: Arm Label: Increase mesalamine dose by 2.4g/day; Type: EXPERIMENTAL; Interventions: Drug: mesalamine | Arm Label: Maintain mesalmine dose; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): Increase mesalamine dose by 2.4g/day
B: Arm Label: Asacol®; Type: EXPERIMENTAL; Interventions: Drug: Asacol® | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine | Intervention Type: DRUG; Name: Asacol®; Assigned to Arm(s): Asacol® | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine
C: Intervention Type: DRUG; Name: SPD476 (mesalazine); Assigned to Arm(s): N/A
D: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression
Brief Summary: This study reports a clinical trial evaluating lamotrigine safety and efficacy as an antidepressant augmentation agent in treatment resistant depression, therefore adding more empirical evidence to the limited number of studies on the use of lamotrigine.


Options:
A: Arm Label: Placebo + ADT Lead-in; Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Double-Blind); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Arm Label: Cariprazine + ADT (Double-Blind); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine, Drug: Antidepressant Therapy (ADT) | Arm Label: Placebo + ADT (Continued Treatment); Type: OTHER; Interventions: Drug: Placebo, Drug: Antidepressant Therapy (ADT) | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine + ADT (Double-Blind) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in | Intervention Type: DRUG; Name: Antidepressant Therapy (ADT); Assigned to Arm(s): Cariprazine + ADT (Double-Blind), Placebo + ADT (Continued Treatment), Placebo + ADT (Double-Blind), Placebo + ADT Lead-in
B: Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A
C: Arm Label: Drug 2mg/Drug 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 5mg, Drug: Aripiprazole 2mg | Arm Label: Placebo/Drug 2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 2mg, Drug: Placebo | Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole 5mg; Assigned to Arm(s): Drug 2mg/Drug 5mg | Intervention Type: DRUG; Name: Aripiprazole 2mg; Assigned to Arm(s): Drug 2mg/Drug 5mg, Placebo/Drug 2mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Drug 2mg, Placebo/Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amide | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Amide; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM
Brief Summary: The purpose of this study is to compare a dose of Symbicort taken once daily with other dosage regimens of Symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults


Options:
A: Arm Label: Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium | Arm Label: Salmeterol or Formoterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Formoterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol or Formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Salmeterol or Formoterol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide and placebo | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide and placebo; Assigned to Arm(s): 2
C: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
D: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine (580299) Co-administrated With a Commercially Available Vaccine in Healthy Female Adolescents
Brief Summary: Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer. Thus, HPV vaccination could complement the existing pre-adolescent/adolescent vaccination programs. This Phase IIIb study is designed to evaluate the immunogenicity and safety of co-administering a commercially available vaccine with GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine as compared to the administration of either vaccine alone.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A) | Arm Label: Group F; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV vaccine (GSK1674330A); Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Group F
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Cervarix & Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV Vaccine (GSK580299) Cervarix TM, Biological: Engerix B | Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV Vaccine (GSK580299) Cervarix TM | Arm Label: Engerix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix B | Intervention Type: BIOLOGICAL; Name: HPV Vaccine (GSK580299) Cervarix TM; Assigned to Arm(s): Cervarix & Engerix Group, Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix B; Assigned to Arm(s): Cervarix & Engerix Group, Engerix Group
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™ | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™; Assigned to Arm(s): Havrix Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modified Ritgens Maneuver for Perineal Protection at Delivery
Brief Summary: The aim of the investigation was to assess whether routine use of the modified Ritgen´s maneuver decreases the risk of anal sphincter injury at delivery, compared with simple manual protection of the perineum.Ritgen´s maneuver means that the fetal chin is reached for between the anus and the coccyx and pulled anteriorly, while using the fingers of the other hand on the fetal occiput to control speed of delivery and keep flexion of the fetal neck.


Options:
A: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ritgens maneuver | Arm Label: II; Type: OTHER; Interventions: Procedure: Standard care (Manual support of the perineum) | Intervention Type: PROCEDURE; Name: Ritgens maneuver; Assigned to Arm(s): I | Intervention Type: PROCEDURE; Name: Standard care (Manual support of the perineum); Assigned to Arm(s): II
B: Arm Label: Perineal device used; Type: OTHER; Interventions: Device: Perineal protection device | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Perineal protection device; Assigned to Arm(s): Perineal device used
C: Arm Label: Perineal Massage & Control; Type: EXPERIMENTAL; Interventions: Other: Perineal massage in childbirth | Intervention Type: OTHER; Name: Perineal massage in childbirth; Assigned to Arm(s): Perineal Massage & Control
D: Arm Label: Anterior shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary delivery of anterior shoulder | Arm Label: Posterior shoulder; Type: EXPERIMENTAL; Interventions: Procedure: Primary delivery posterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery of anterior shoulder; Assigned to Arm(s): Anterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery posterior shoulder; Assigned to Arm(s): Posterior shoulder

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Modified Ritgens Maneuver for Perineal Protection at Delivery
Brief Summary: The aim of the investigation was to assess whether routine use of the modified Ritgen´s maneuver decreases the risk of anal sphincter injury at delivery, compared with simple manual protection of the perineum.Ritgen´s maneuver means that the fetal chin is reached for between the anus and the coccyx and pulled anteriorly, while using the fingers of the other hand on the fetal occiput to control speed of delivery and keep flexion of the fetal neck.


Options:
A: Arm Label: hands on; Type: EXPERIMENTAL; Interventions: Procedure: hands on | Arm Label: hands off; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: hands on; Assigned to Arm(s): hands on
B: Arm Label: Anterior shoulder; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Primary delivery of anterior shoulder | Arm Label: Posterior shoulder; Type: EXPERIMENTAL; Interventions: Procedure: Primary delivery posterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery of anterior shoulder; Assigned to Arm(s): Anterior shoulder | Intervention Type: PROCEDURE; Name: Primary delivery posterior shoulder; Assigned to Arm(s): Posterior shoulder
C: Arm Label: CONTROL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: VOCALIZATION; Type: EXPERIMENTAL; Interventions: Other: vocalization | Intervention Type: OTHER; Name: vocalization; Assigned to Arm(s): VOCALIZATION
D: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ritgens maneuver | Arm Label: II; Type: OTHER; Interventions: Procedure: Standard care (Manual support of the perineum) | Intervention Type: PROCEDURE; Name: Ritgens maneuver; Assigned to Arm(s): I | Intervention Type: PROCEDURE; Name: Standard care (Manual support of the perineum); Assigned to Arm(s): II

Answer: D